Recent trials evaluating allogeneic transplant on a donor versus no donor basis.¶
| . | Disease-Free Survival* (%) . | Overall Survival* (%) . | ||
|---|---|---|---|---|
| Trial . | Donor . | No Donor . | Donor . | No Donor . |
| Abbreviations: EORTC/GIMEMA, European Organization for Research and Treatment of Cancer/Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto; AML, acute myeloid leukemia; GOELAM, Groupe Ouest Est Leucemies Aigues Myeloblastiques; MRC, Medical Research Council. | ||||
| ¶ All patients having a donor available were regarded as transplant recipients. | ||||
| * % at 4 years or beyond | ||||
| †P = .01 ‡ P = .046 | ||||
| EORTC/GIMEMA AML 8 | 46 | 33† | 48 | 40 |
| GOELAM | 44 | 38 | 53 | 53 |
| MRC AML 10 | 50 | 42 | 55 | 50 |
| Intergroup | 43 | 35 | 46 | 52 |
| EORTC/GIMEMA AML 10 | 51.4 | 41.2‡ | 58 | 49.4 |
| . | Disease-Free Survival* (%) . | Overall Survival* (%) . | ||
|---|---|---|---|---|
| Trial . | Donor . | No Donor . | Donor . | No Donor . |
| Abbreviations: EORTC/GIMEMA, European Organization for Research and Treatment of Cancer/Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto; AML, acute myeloid leukemia; GOELAM, Groupe Ouest Est Leucemies Aigues Myeloblastiques; MRC, Medical Research Council. | ||||
| ¶ All patients having a donor available were regarded as transplant recipients. | ||||
| * % at 4 years or beyond | ||||
| †P = .01 ‡ P = .046 | ||||
| EORTC/GIMEMA AML 8 | 46 | 33† | 48 | 40 |
| GOELAM | 44 | 38 | 53 | 53 |
| MRC AML 10 | 50 | 42 | 55 | 50 |
| Intergroup | 43 | 35 | 46 | 52 |
| EORTC/GIMEMA AML 10 | 51.4 | 41.2‡ | 58 | 49.4 |